Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water

Environmental Science and Pollution Research

Volumn 17, Issue 2, 2010, Pages 486-496

  Kümmerer, Klaus ^a   Al Ahmad, Ali ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cancer; Cyclophosphamide; Drinking water; Excretion; Hospital effluent; Ifosfamide; Intake; Life span; Risk; Surface water

Indexed keywords

BIODEGRADATION; CANCER; CHEMOTHERAPY; CHILD HEALTH; DRINKING WATER; DRUG; GENOTOXICITY; HEALTH RISK; METABOLITE; PHOTOCHEMISTRY; POLLUTION EXPOSURE; RISK ASSESSMENT; SEWAGE TREATMENT; WATER POLLUTION;

GERMANY;

ALKYLATING AGENT; CARCINOGEN; CYCLOPHOSPHAMIDE; FRESH WATER; IFOSFAMIDE;

ARTICLE; CHEMISTRY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMAN; RISK; RISK ASSESSMENT; SEWAGE; WATER POLLUTANT; WATER SUPPLY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOGENS, ENVIRONMENTAL; CYCLOPHOSPHAMIDE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FRESH WATER; HUMANS; IFOSFAMIDE; ODDS RATIO; RISK ASSESSMENT; SEWAGE; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

EID: 77449118980     PISSN: 09441344     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11356-009-0195-4     Document Type: Article

References (62)

1. Allwood M, Wright P (1993) The cytotoxics handbook. 2nd edn. Oxford Radcliffe.
2. ASTA Medica AG (1992) Information for users of cyclophosphamide and ifosfamide. Frankfurt.
3. Bagley CM Jr, Bostick FW, De Vita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226-233.
4. Bier V, Jürgens H, Etspüler G et al (1987) 120-h continuous infusion of ifosfamide alone and in combination with cis-platinum in children and adolescents with recurrent Ewing's sarcoma. Contr Oncol 26: 131-138.
5. Boos J, Welslau U, Ritter J et al (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemoth Pharm 28: 455-460.
6. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1992) Ifosfamide and its 'side chain oxidized' metabolites-urinary excretion under different pediatric treatment schedules. Klin Pädiatr 204: 299-305.
7. Brock N, Pohl J (1987) The basis of modern ifosfamide therapy. Contrib Oncol 26: 1-11.
8. Buerge IJ, Buser HR, Poiger T, Müller MD (2006) Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 40: 7242-7250.
9. Christensen FM (1998) Pharmaceuticals in the environment-a human risk? Regul Toxicol Pharm 28: 212-221.
10. Clever LH, Omenn GS (1988) Hazards for health care workers. Annu Rev Publ Health 9: 273-303.
11. Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME (1995) Considering pharmacokinetic and mechanistic information in cancer risk assessment for environmental contaminants: examples with vinylchloride and trichloroethylene. Chemosphere 31: 2561-2578.
12. Cooke J, Williams J, Morgan RJ, Cooke P, Calvert RT (1991) Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 48: 1199-1205.
13. Dieter HH, Mückter H (2007) Assessment of so called organic trace compounds in drinking water from the regulatory, health and aesthetic-quality points of view, with special consideration given to pharmaceuticals. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 50: 322-331.
14. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt R, Fruhmann G (1994) Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 51: 229-233.
15. European Environment Agency, WHO Regional Office for Europe (2002) Children's health and environment: a review of evidence. Environmental issue report No 29, EEA, Copenhagen, 2002.
16. European Union, Direction General III (1995) Assessment of potential risks to the environment posed by medical products for human use (excluding products containing live genetically modified organisms. No. 5504/94 Draft 6, version 4, Brusse.
17. Fichtner I, Nowak C (1987) Pharmacological and toxicological effects of ifosfamide (Haloxan®) combined with mesna (Uromitexan®) in different urine tumor models. Contrib Oncol 26: 93-104.
18. Gilard V, Malet-Martino MC, De Forni M, Niemeyer U, Ader JC, Martino R (1993) Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosporous-31 nuclear magnetic resonance spectroscopy. Cancer Chemoth Pharm 31: 387-394.
19. Goren MP (1991) Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high performance liquid chromatography. J Chromatogr - Biomed 570: 351-360.
20. Greene MH, Harris EIL, Gershenson DM, Malkasian GD, Melton LJ, Dembo AJ, Bennet JM, Moloney WC, Boice JC (1986) Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105: 360-367.
21. Grochow LB, Calvin M (1983) Clinical pharmacokinetics of cyclophosphamide. In: Ames MM, Povis GG, Kovach IS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, New York.
22. Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Möhner M, Kaldor JM, Day NE (1987) Risk of leukemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Brit J Cancer 55: 213-218.
23. Hansch C, Leao A, Hoekman D (1995) Exploring QSAR: Hydrophobic, electronic and stric conctants. American Chemical Society, Washington DC.
24. Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131: 5-17.
25. International Agency for Research on Cancer (1975) Cyclophosphamide. IARC Monographs on the evaluation of the carcinogenic risk of chemicals. Lyon 9: 135-156.
26. International Agency for Research on Cancer (1981) Cyclophosphamide. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals. Lyon 26: 165-202.
27. Jjemba PK (2008) Pharmaecology. Wiley, Hoboken, NJ, p 105.
28. Kim S, Aga DS (2007) Potential ecological and human health impacts of antibiotics and antibiotic-resistant bacteria from waste water treatment plants. J Toxicol Env Heal B 10: 559-573.
29. Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78: 44-49.
30. Kinlen LJ, Sheil AG, Peto J (1979) Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. Br Med J iv: 1461-1466.
31. Kinlen LJ, Peto J, Doll R, Sheil AG (1981) Cancer in patients treated with immunosuppressive drugs. Br Med J 282: 474.
32. Knight A, Asklin J, Granath F, Sparen P, Ekbom A (2004) Urinary bladder cancer in Wegener's granulomatosis: risk and relation to cyclophosphamide. Ann Rheum Dis 63: 1307-1311.
33. Kümmerer K (2007) Sustainable from the very beginning. Rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9: 899-907.
34. Kümmerer K (Ed.) (2008) Pharmaceuticals in the environment. Sources, fate, effects, and risk. 3rd ed. Springer, Heidelberg.
35. Kümmerer K, Steger-Hartmann T, Baranyai A (1996) Evaluation of the biological degradation of the antineoplastics cyclophosphamide and ifosfamide with the closed bottle test (OECD 301 D). Zbl Hyg 198: 215-225.
36. Kümmerer K, Steger-Hartmann T, Meyer M (1997) Biodegradability of the anti-tumour agent ifosfamide and its occurrence in sewage. Water Res 31: 2705-2710.
37. Kümmerer K, Al-Ahmad A, Bertram B, Wießler M (2000) Biodegradability of antineoplastic compounds in screening tests: improvement by glucosidation and influence of stereo-chemistry. Chemosphere 40: 767-773.
38. Martino R, Crasnier F, Chouini Lalanne N, Gilard V, Niemeyer U, de Forni M, Malet-Martino MC (1992) A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with phosporus-31 nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260: 1133-1144.
39. Matney TS, Ngyuen TV, Connor TH, Ana WJ, Theiss JC (1985) Genotoxic classification of anti-cancer drugs. Teratogen Carcin Mut 5: 319-328.
40. Momerency G, van Cauwenberghe K, De Bruijn EA, van Oosterom AT, Highley MS, Harper PG (1994a) Determination of ifosfamide and seven metabolites in blood plasma, as stable trifluoracetyl derivatives, by electron capture chemical ionization GC-MS. J High Res Chromatog 17: 655-661.
41. Momerency G, van Cauwenberghe K, Slee PH, van Oosterom AT, De Bruijn EA (1994b) The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoracetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 23: 149-158.
42. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI (1985) Risk of acute non-lymphocytic leukaemia and preleukaemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 103: 195-200.
43. Plotz PH, Kippel HJ, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91: 221-223.
44. Richardson ML, Bowron JM (1985) The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37: 1-12.
45. Saul G, Matthias M, Rose H, Pradel I (1979) Excretion pattern of alkylating metabolites in urine following cyclophosphamide treatment of tumor patients: influence of application route, dosage, liver and kidney function. J Cancer Res Clin 94: 277-286.
46. Schecker J, Al-Ahmad A, Bauer MJ, Zellmann H, Kümmerer K (1998) Elimination des Zytostatikums Ifosfamid während der simulierten Zersetzung von Hausmüll im Labormaßstab. (Elimination of the cytotoxic ifosfamide during the simulation of household waste in laboratory scale) Umweltwiss Schadst Forsch 10: 339-344.
47. Schulman LJ, Sargent EV, Naumann BD, Faria EC, Dolan DG, Wargo JP (2002) A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess 8: 657-680.
48. Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD (2005) Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharm 42: 296-312.
49. Sessink PJM, Kroese ED, van Kranen HJ, Bos RP (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occ Env Hea 67: 317-323.
50. Sorsa M, Pyy L, Salomaa S, Nylund L, Yager JW (1988) Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 204: 465-479.
51. Statistisches Bundesamt (German Federal Statistical Agency) (1990) Umweltschutz, Fachserie 19, Reihe 1. 2 Abfallbeseitigung im Produzierenden Gewerbe. Metzler Pöschel, Wiesbaden (1994).
52. Steger-Hartmann T (1995) Thesis, University of Freiburg.
53. Steger-Hartmann T, Kümmerer K, Schecker J (1996) Trace analysis of the anti-neoplastics ifosfamide and cyclophosphamide in sewage water by two step solid phase extraction and GC/MS. J Chromatogr A 726: 179-184.
54. Steger-Hartmann T, Kümmerer K, Hartmann A (1997) Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotox Environ Safe 36: 174-179.
55. Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM (1994) Risk of leukaemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer I 86: 1450-1457.
56. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adam J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice JD (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer I 87: 524-530.
57. Umweltbundesamt (2004) Umweltbedingte Gesundheitsrisisken-was ist bei Kindern anders als bei Erwachsenen? Berlin.
58. Umweltbundesamt (2003) Bewertung der Anwesenheit teil- oder nicht bewertbarer Stoffe im Trinkwasser aus gesundheitlicher Sicht. (Recommendation of the Federal Environment Agency of March 2003 'Assessing the presence of substances in drinking water without (adequate) toxicological database from the health point of view') Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 46: 249-251.
59. US EPA (2003) Adjusting for youth, update cancer risk guidelines. Environ Health Persp 111: A 708-710.
60. Wagner T, Ehinger G (1987) Self-induction of cyclophosphamide and ifosfamide metabolism by repeated high dose-treatment. Contrib Oncol 26: 69-75.
61. Webb S, Ternes T, Gibert M, Olejniczak K (2003) Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142: 157-167.
62. Zuccato E, Calamari D, Natangeleo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. Lancet 355: 1789-1790.